SCHEMBL6772984

SCHEMBL6772984

CCOCn1nnc(-c2ccnc(Cl)n2)c1-c1cccc(C(F)(F)F)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 4/20 0.44
KMO O15229 1/20 0.37
GRIN2B Q13224 5/20 0.35
GRIN1 Q05586 4/20 0.35
RXRA P19793 1/20 0.35
CTSS P25774 1/20 0.35
CTSK P43235 1/20 0.35
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35
KMT2A Q03164 1/20 0.35
GPR55 Q9Y2T6 1/20 0.35
XPO1 O14980 1/20 0.35
POLB P06746 1/20 0.34
MAPK13 O15264 2/20 0.34
MAPK12 P53778 2/20 0.34
MAPK11 Q15759 2/20 0.34
GSK3B P49841 2/20 0.34
CDK2 P24941 1/20 0.34
TLR8 Q9NR97 1/20 0.34
UBE2N P61088 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6670050 0.93 MAPK14 (0.44) MAPK14KMOMEN1MAPTKMT2A
SCHEMBL6669636 0.85 MAPK14 (0.40) MAPK14KMOGPR55MAPK13MAPK12
SCHEMBL6613288 0.81 MAPK14 (0.54) MAPK14MAPT
SCHEMBL6772180 0.78 MAPK14 (0.42) MAPK14KMOGPR55MAPK13MAPK12
SCHEMBL6784447 0.77 MAPK14 (0.39) MAPK14KMOMAPK13MAPK12MAPK11
SCHEMBL6784449 0.76 MAPK14 (0.45) MAPK14MAPK13MAPK12MAPK11GSK3B
SCHEMBL6612309 0.74 MAPK14 (0.54) MAPK14MAPT
SCHEMBL6786356 0.74 MAPK14 (0.54) MAPK14MAPK13MAPK12MAPK11
SCHEMBL6612844 0.74 MAPK14 (0.54) MAPK14MAPK13MAPK12MAPK11
SCHEMBL6612848 0.74 MAPK14 (0.54) MAPK14MAPK13MAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727364-B2 ANTIINFLAMMATORY AGENTS THE PROCTER & GAMBLE COMPANY 2004-04-27 US disclosed
US-20030013712-A1 Triazole compounds useful in treating diseases associated with unwanted cytokine activity PROCTER & GAMBLE COMPANY, THE 2003-01-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030013712-A1 Triazole compounds useful in treating diseases associated with unwanted cytokine activity IL4, IL1A, IL2 MAPK14 3429/4885KMO 516/4885GRIN2B 3381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.